Rhythm Pharmaceuticals, Inc. (RYTM)

NASDAQ: RYTM · Real-Time Price · USD

92.73

-5.34 (-5.45%)

At close: Feb 27, 2026, 4:00 PM EST

92.66

-0.07 (-0.08%)

After-hours: Feb 27, 2026, 7:32 PM EST

Rhythm Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	189.76	130.13	77.43	23.64	3.15
Revenue Growth (YoY)	45.83%	68.06%	227.56%	649.46%	-
Cost of Revenue	19.49	13.37	9.3	2.13	0.6
Gross Profit	170.27	116.76	68.13	21.51	2.56
Selling, General & Admin	194.94	144.3	117.53	92.03	68.49
Research & Development	167.34	237.96	134.95	108.63	104.13
Operating Expenses	362.28	382.26	252.48	200.66	172.61
Operating Income	-192.02	-265.5	-184.36	-179.16	-170.06
Interest Expense	-20.58	-20.6	-13.89	-5.2	-
Interest & Investment Income	15.29	14.71	13.95	4.03	0.45
Other Non Operating Income (Expenses)	1.26	11.14	0.19	0.25	100
EBT Excluding Unusual Items	-196.04	-260.26	-184.11	-180.08	-69.61
Gain (Loss) on Sale of Investments	-	-	-	-1.04	-
Pretax Income	-196.04	-260.26	-184.11	-181.12	-69.61
Income Tax Expense	0.5	0.35	0.56	-	-
Net Income	-196.54	-260.6	-184.68	-181.12	-69.61
Preferred Dividends & Other Adjustments	5.38	3.97	-	-	-
Net Income to Common	-201.92	-264.57	-184.68	-181.12	-69.61
Shares Outstanding (Basic)	65	61	58	52	50
Shares Outstanding (Diluted)	65	61	58	52	50
Shares Change (YoY)	6.54%	5.76%	10.65%	5.08%	12.40%
EPS (Basic)	-3.11	-4.34	-3.20	-3.47	-1.40
EPS (Diluted)	-3.11	-4.34	-3.20	-3.47	-1.40
Free Cash Flow	-	-113.88	-136.2	-173.71	-146.44
Free Cash Flow Per Share	-	-1.87	-2.36	-3.33	-2.95
Gross Margin	89.73%	89.73%	87.99%	90.98%	81.01%
Operating Margin	-101.19%	-204.04%	-238.10%	-757.92%	-5391.85%
Profit Margin	-106.41%	-203.32%	-238.52%	-766.22%	-2207.10%
Free Cash Flow Margin	-	-87.51%	-175.91%	-734.87%	-4642.90%
EBITDA	-190.59	-263.94	-182.6	-177.49	-168.9
EBITDA Margin	-100.44%	-202.83%	-235.83%	-	-
D&A For EBITDA	1.42	1.56	1.76	1.67	1.16
EBIT	-192.02	-265.5	-184.36	-179.16	-170.06
EBIT Margin	-101.19%	-204.04%	-238.10%	-	-
Revenue as Reported	189.76	130.13	77.43	23.64	3.15

Updated Feb 26, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q